Untitled

Yokogawa, Koiçhi; Iwashita, Satsuki; Kubota, Akira; Sasaki, Youko; Ishizaki, Junko; Kawahara, Masami; Matsushita, Ryo; Kimura, Kazuko; Ichimura, Fujio; Miyamoto, Ken‐ichi

doi:10.1023/a:1013046229699

Cited by 46 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imipenem, Meropenem, Doripenem, Ertapenem, and Panipenem antibiotics decrease the serum concentrations of valproic acid likely by increasing the metabolism of VPA to VPA glucuronide as well as the renal clearance of VPA glucuronide and by inhibiting the intestinal absorption of VPA [111, 112]. Valproic acid has been shown to significantly increase the plasma concentrations of lamotrigine (doubling the half-life) [113–115] potentially leading to serious and life-threatening rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis, but also disabling tremors and ataxia, known as secondary effects of lamotrigine [116, 117].…”

Section: Drug's Interactionsmentioning

confidence: 99%

Molecular and Therapeutic Potential and Toxicity of Valproic Acid

Chateauvieux

Morceau

Dicato

et al. 2010

Journal of Biomedicine and Biotechnology

374

301

View full text Add to dashboard Cite

Valproic acid (VPA), a branched short-chain fatty acid, is widely used as an antiepileptic drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of Gamma Amino Butyrate (GABA) transaminobutyrate and of ion channels. VPA was recently classified among the Histone Deacetylase Inhibitors, acting directly at the level of gene transcription by inhibiting histone deacetylation and making transcription sites more accessible. VPA is a widely used drug, particularly for children suffering from epilepsy. Due to the increasing number of clinical trials involving VPA, and interesting results obtained, this molecule will be implicated in an increasing number of therapies. However side effects of VPA are substantially described in the literature whereas they are poorly discussed in articles focusing on its therapeutic use. This paper aims to give an overview of the different clinical-trials involving VPA and its side effects encountered during treatment as well as its molecular properties.

show abstract

Section: Drug's Interactionsmentioning

confidence: 99%

Molecular and Therapeutic Potential and Toxicity of Valproic Acid

Chateauvieux

Morceau

Dicato

et al. 2010

Journal of Biomedicine and Biotechnology

374

301

View full text Add to dashboard Cite

show abstract

“…AAP is a serine-protease enzyme, however, its unique structure and multimerization state seem to create such a seclusion of its active site that potentiates interactions very much unlike those of regular serine-proteases, the most striking example of which is its interaction with and inhibition by carbapenem antibiotics. 25–28 Furthermore, AAP was suggested to be able to catalyze the cleavage of amyloid oligomers formed in the progress of Alzheimer's disease. 29 It was also shown to be a key protein in cellular response to DNA-damage 30 and oxidative stress, 31,32 and was proposed to be a potential tumor suppressor.…”

Section: Introductionmentioning

confidence: 99%

Cryo-EM structure of acylpeptide hydrolase reveals substrate selection by multimerization and a multi-state serine-protease triad

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Animal studies suggest a reduced intestinal absorption and enterohepatic recirculation [ 23 ]. An increase of glucuronidation and a decrease of hepatic hydrolysis resulting in an increased renal clearance of VPA-glucuronide have been postulated [ 24 , 25 , 26 , 27 ]. Inhibition of efflux of VPA from erythrocytes and its accumulation have also been described [ 28 , 29 ].…”

Section: Resultsmentioning

confidence: 99%

Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units—A Multicenter Delphi Study

et al. 2021

View full text Add to dashboard Cite

Patients in intensive care units (ICUs) are at high risk of drug–drug interactions (DDIs) due to polypharmacy. Little is known about type and frequency of DDIs within German ICUs. Clinical pharmacists’ interventions (PI) recorded in a national database (ADKA-DokuPIK) were filtered for ICU patients. Binary DDIs involving ≥1 anti-infective agent with >1 database entry were selected. A modified two-step Delphi process with a group of senior hospital pharmacists was employed to evaluate selected DDIs for clinical relevance by using a five-point scale and to develop guidance for clinical practice. In total, 16,173 PI were recorded, including 1836 (11%) DDIs in the ICU setting. Of the latter, 41% (756/1836) included ≥1 anti-infective agent, 32% (590/1836) were binary DDIs, and 25% (455/1836) were listed at least twice. This translates into 88 different DDIs, 74% (65/88) of which were rated as being clinically relevant by our expert panel. The majority of DDIs (76% [67/88]) included macrolides, antifungals, or fluoroquinolones. This percentage was even higher in DDIs being rated as clinically relevant by the experts (85% [55/65]). It is noted that an inter-professional discussion and approach is needed in the individual patient management of DDIs. The guidance developed might be a tool for decision support.

show abstract

Untitled

Abstract: The increase of the total clearance of VPA caused by MEPM appears to be a consequence of increased renal clearance of VPA-G, as well as suppression of VPA-G hydrolysis in the liver.

Cited by 46 publications

References 10 publications

Molecular and Therapeutic Potential and Toxicity of Valproic Acid

Molecular and Therapeutic Potential and Toxicity of Valproic Acid

Cryo-EM structure of acylpeptide hydrolase reveals substrate selection by multimerization and a multi-state serine-protease triad

Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units—A Multicenter Delphi Study

Contact Info

Product

Resources

About